PAYER STRATEGY
Why Getting Covered is Harder Than Getting Cleared
Real-world evidence isn't a post-approval problem. Here's why it has to be part of your strategy from day one.
MAY 15, 2026
Medical device companies invest years and significant resources demonstrating that their technology works, and most succeed. They conduct rigorous randomized controlled trials, achieve statistically meaningful outcomes, and navigate the regulatory pathway to FDA clearance. What many do not anticipate is that clearance is the beginning of a second, distinct evidentiary challenge, one with different decision-makers, different standards of evidence, and different questions that need answering before coverage follows.
Regulatory approval and payer coverage are not the same problem. The FDA evaluates whether a device works under controlled trial conditions, prioritizing internal validity and causal evidence of efficacy. Payers evaluate whether a device delivers measurable clinical and financial value in their patient populations, under real clinical conditions, at a cost that justifies coverage relative to existing alternatives. These are structurally different questions, and the evidence required to answer them is correspondingly different. Companies that treat regulatory approval as the endpoint of evidence generation often find themselves well past clearance with a coverage gap they did not see coming, and without the data they need to close it.
A REGULATORY ENVIRONMENT THAT HAS KEPT PACE WITH THE PROBLEM
The growing acceptance of real-world evidence in regulatory and coverage decision-making reflects how central this evidence gap has become to the medical device landscape. The 21st Century Cures Act in 2016 accelerated the broader adoption of real-world evidence across product evaluation. By 2018, the FDA had formalized a framework for evaluating real-world evidence in support of regulatory decision-making. In 2023, the Center for Devices and Radiological Health approved the first medical device label expansion based entirely on real-world evidence derived from electronic health records, establishing a precedent that has meaningfully shaped how the field thinks about post-market evidence strategy.
Most recently, in December 2025, the FDA updated its guidance on real-world evidence for medical devices, removing a longstanding requirement that sponsors provide individually identifiable patient-level data when submitting real-world evidence in marketing applications. Previously, this requirement had rendered large de-identified datasets, including claims databases, disease registries, and EHR repositories, effectively impractical for use in regulatory submissions, creating both logistical and financial barriers to using the most valuable sources of population-level data. The updated guidance evaluates evidence on a case-by-case basis, with emphasis on whether the data are scientifically sound and fit for their intended purpose. The FDA has indicated its intent to consider extending similar changes to drugs and biologics. The direction of travel is clear, and companies that build real-world evidence generation into their product strategy early are better positioned to take advantage of these evolving frameworks, rather than scrambling to assemble evidence after the regulatory environment has moved.
WHAT PAYERS ARE ACTUALLY ASKING
A compelling payer value proposition requires answering three distinct questions, and the clinical trial, however well-designed, answers only one of them.
The first is clinical efficacy: does the device work? This is what the randomized controlled trial is designed to demonstrate. Its strength is internal validity, the ability to establish a causal relationship between the intervention and the outcome under controlled conditions. It remains the evidentiary standard for regulatory approval, and appropriately so.
The second is cost-effectiveness: does the device deliver financial value beyond its clinical benefit? This is where economic analyses enter the picture, quantifying what coverage costs relative to current standards of care and what it saves downstream in hospitalizations, care utilization, and disease progression. Payers operating under sustained pressure to manage expenditures are increasingly driven by economic considerations in coverage decisions, and clinical effectiveness alone rarely resolves the budget impact question.
The third is generalizability: how does the device perform in the real world, outside the controlled conditions of the trial? Trial populations are, by design, selected and monitored in ways that do not reflect routine clinical practice. Real patients present with more comorbidities, lower adherence rates, and greater demographic diversity than the average trial enrollee. Payers need assurance that outcomes demonstrated under protocol conditions will replicate among their actual members, in the care settings where their members receive treatment. This is precisely the question real-world evidence is designed to answer.
Importantly, these three elements are not competing forms of evidence but complementary ones. The randomized controlled trial establishes that the device works. Real-world evidence establishes that it works for the patients payers are actually covering, in the settings where care is actually delivered. Both are required to build a case that moves a payer from skeptical to covered.
WHY METHODOLOGICAL QUALITY IS NOT OPTIONAL
Something the field does not always say directly: payer acceptance of real-world evidence is not automatic, and the skepticism payers bring to RWE submissions is legitimate and grounded in a real history of methodologically weak studies.
The most consistently cited payer concern is evidence quality, specifically the potential for bias and confounding that arises from the non-randomized nature of observational data. Lack of standardization in study design, limited transparency in analytic methods, and inconsistency in how real-world evidence is communicated have all contributed to payers being reluctant to weight this evidence heavily in coverage decisions, even when they understand its value and want to use it. The Academy of Managed Care Pharmacy published formal real-world evidence standards in 2025 specifically to address the gap between payer interest in real-world evidence and their confidence in evaluating it, signaling that the infrastructure for more consistent payer use of this evidence is still being built.
This means the bar for credible real-world evidence is genuinely high. A retrospective claims analysis with inadequate control for confounding will not move a payer, regardless of how favorable the results appear. A pre-specified study with transparent methods, appropriate comparators, outcomes that correspond to payer priorities, and a study population that reflects the covered population has a meaningful chance of doing so. The difference is not the data source. It is the rigor and intentionality of the design built around it, and whether that design was constructed to answer the payer's question, not the sponsor's.
EVIDENCE STRATEGY AS A PRODUCT DEVELOPMENT DECISION
The most consequential mistake companies make is treating real-world evidence as a post-approval problem. By the time a device is in payer negotiations, it is too late to design a data collection strategy that would have answered the coverage question. The outcomes payers care most about, real-world effectiveness, cost impact, and performance across patient subgroups, have to be systematically captured from the point of product deployment, and in some cases earlier, to be available when they are needed.
This requires identifying evidence gaps in parallel with clinical development, selecting data sources that capture payer-relevant outcomes, and designing real-world evidence studies with the same methodological care applied to the trial itself. Companies that approach evidence strategy this way arrive at payer conversations with a coherent, complete evidence package that addresses the three questions above. Companies that do not find themselves investing in retrospective data reconstruction that is more expensive, less reliable, and often insufficient to meet the evidentiary standard payers apply.
Real-world evidence is not a regulatory afterthought or a supporting exhibit to the clinical trial. For medical device companies competing in a market where payer scrutiny is intensifying and coverage decisions carry significant commercial consequence, it is a strategic asset that has to be planned, designed, and executed from the beginning.
This article draws on a presentation co-delivered with Ellyn Russo, DMSc, at the MassMedic Regulatory, Payment and Policy Conference in Boston, MA, June 2025